BR112014007376A2 - método de proporcionar por via oral uma substância bioativa a um indivíduo em necessidade da mesma, forma de dosagem oral e composição de dosagem oral - Google Patents

método de proporcionar por via oral uma substância bioativa a um indivíduo em necessidade da mesma, forma de dosagem oral e composição de dosagem oral

Info

Publication number
BR112014007376A2
BR112014007376A2 BR112014007376A BR112014007376A BR112014007376A2 BR 112014007376 A2 BR112014007376 A2 BR 112014007376A2 BR 112014007376 A BR112014007376 A BR 112014007376A BR 112014007376 A BR112014007376 A BR 112014007376A BR 112014007376 A2 BR112014007376 A2 BR 112014007376A2
Authority
BR
Brazil
Prior art keywords
oral dosage
bioactive substance
phenylephrine
aka
inhibitors
Prior art date
Application number
BR112014007376A
Other languages
English (en)
Inventor
K Ritter Joseph
M Gerk Phillip
H Barr William
Original Assignee
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Commonwealth filed Critical Univ Virginia Commonwealth
Publication of BR112014007376A2 publication Critical patent/BR112014007376A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo “método de proporcionar por via oral uma substância bioativa a um indivíduo em necessidade da mesma, forma de dosagem oral e composição de dosagem oral” a presente invenção se refere ao metabolismo pré-sistêmico no intestino de substâncias bioativas tais como fenilefrina que é evitado por administrar a um indivíduo (humano ou animal) a substância bioativa (por exemplo, fenilefrina) em combinação com um ou mais inibidores de sulfatização (por exemplo, enzimas sulfotransferase aka sults). isso também pode ser aumentado ao se co-administrar inibidores de monoamina oxidases aka, maos, e uridina difosfato glucoronysl transferases, aka ugts. preferivelmente os inibidores são compostos gras. os um ou mais compostos inibidores inibem as enzimas responsáveis pelo rápido metabolismo pré-sistêmico, assim permitindo que as substâncias bioativas (por exemplo, fenilefrina) seja mais rapidamente absorvida intacta dentro do sistema circulatório. 1/1
BR112014007376A 2011-09-27 2012-09-27 método de proporcionar por via oral uma substância bioativa a um indivíduo em necessidade da mesma, forma de dosagem oral e composição de dosagem oral BR112014007376A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161539530P 2011-09-27 2011-09-27
US201161544396P 2011-10-07 2011-10-07
PCT/US2012/057588 WO2013049365A2 (en) 2011-09-27 2012-09-27 Selective metabolic approach to increasing oral bioavailability of phenylephrine and other phenolic bioactives

Publications (1)

Publication Number Publication Date
BR112014007376A2 true BR112014007376A2 (pt) 2017-04-04

Family

ID=47996740

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014007376A BR112014007376A2 (pt) 2011-09-27 2012-09-27 método de proporcionar por via oral uma substância bioativa a um indivíduo em necessidade da mesma, forma de dosagem oral e composição de dosagem oral

Country Status (15)

Country Link
US (1) US9616033B2 (pt)
EP (1) EP2760441A2 (pt)
JP (1) JP2014527999A (pt)
KR (1) KR20140097135A (pt)
AU (1) AU2012316001A1 (pt)
BR (1) BR112014007376A2 (pt)
CA (1) CA2849473A1 (pt)
CL (1) CL2014000747A1 (pt)
CO (1) CO6970592A2 (pt)
IL (1) IL231635A0 (pt)
MX (1) MX2014003606A (pt)
PE (1) PE20142043A1 (pt)
RU (1) RU2014116639A (pt)
SG (1) SG11201400897UA (pt)
WO (1) WO2013049365A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2908583A1 (en) * 2013-04-08 2014-10-16 Virginia Commonwealth University Compositions to alleviate presystemic metabolism of opioids
HUE051900T2 (hu) 2014-06-20 2021-03-29 Hermes Arzneimittel Gmbh Íz-leplezett orális gyógyászati készítmény
PT3174531T (pt) * 2014-07-30 2020-03-05 Merck Patent Gmbh Composição passível de compressão direta contendo celulose microcristalina
KR101621426B1 (ko) 2014-08-20 2016-05-16 선문대학교 산학협력단 신규한 알파-망고스틴 글리코시드 유도체 및 이의 제조방법
FR3027228B1 (fr) * 2014-10-20 2016-12-09 Valbiotis Composition comprenant un melange d'extraits vegetaux et utilisation pour agir sur le metabolisme glucidique et/ou lipidique
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9402834B2 (en) 2014-10-21 2016-08-02 Ions Pharmaceutical S.À R.L. Human therapeutic agents
US10123991B2 (en) 2015-05-15 2018-11-13 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
CN107515307A (zh) * 2017-10-13 2017-12-26 基蛋生物科技股份有限公司 一种干式免疫心血管八指标检测试纸条
WO2020049588A1 (en) * 2018-09-05 2020-03-12 THAKKAR Hetal Paresh Technology for enhancing bioavalaibility of selective estrogen receptor modulator (serm)
CN113671093A (zh) * 2020-05-13 2021-11-19 上海大学 快速检测人体尿液中对羟基苯甲酸类物质的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493827A (en) 1983-11-14 1985-01-15 Ronald Valle Method of inducing sleep
EP0695175A1 (en) * 1993-04-30 1996-02-07 The Procter & Gamble Company Coated pharmaceutical compositions
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US6759062B2 (en) 2000-02-23 2004-07-06 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
CA2424021A1 (en) 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine compositions and uses thereof
US20030215462A1 (en) 2001-12-21 2003-11-20 Wacher Vincent J. Use of UGT inhibitors to increase bioavailability
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20070160688A1 (en) * 2006-01-10 2007-07-12 Eric Marchewitz Use of flavonoids to increase blood serum levels of dehydroepiandrosterone
US20070160689A1 (en) * 2006-01-12 2007-07-12 Everett Laboratories, Inc. Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
AU2007254821B2 (en) * 2006-06-01 2013-11-14 Bayer Consumer Care Ag Sustained release pharmaceutical formulation comprising phenylephrine
US20080069874A1 (en) 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for Prevention and Treatment of Rhinitis
WO2009143297A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Carbonate prodrugs and methods of using the same

Also Published As

Publication number Publication date
JP2014527999A (ja) 2014-10-23
KR20140097135A (ko) 2014-08-06
WO2013049365A2 (en) 2013-04-04
CA2849473A1 (en) 2013-04-04
US9616033B2 (en) 2017-04-11
SG11201400897UA (en) 2014-04-28
WO2013049365A3 (en) 2013-05-30
RU2014116639A (ru) 2015-11-10
US20140221426A1 (en) 2014-08-07
PE20142043A1 (es) 2014-12-18
AU2012316001A1 (en) 2014-04-10
IL231635A0 (en) 2014-05-28
CO6970592A2 (es) 2014-06-13
MX2014003606A (es) 2015-01-16
CL2014000747A1 (es) 2015-02-27
EP2760441A2 (en) 2014-08-06

Similar Documents

Publication Publication Date Title
BR112014007376A2 (pt) método de proporcionar por via oral uma substância bioativa a um indivíduo em necessidade da mesma, forma de dosagem oral e composição de dosagem oral
BR112022004248A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer
BR112017024777A2 (pt) uso de uma composiçao farmacêutica e de um antibiótico não absorvível para tratamento de transtorno do espectro autista referência cruzada a pedidos relacionados?
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
BR112014029115A8 (pt) Composto, composição farmacêutica, e, uso de um composto ou composição
BR112013006953A2 (pt) composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença
BR112013002112A2 (pt) composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável ou n-óxido, ou um solvato ou hidrato do mesmo, ou de uma composição
BR112012023021A2 (pt) compostos de indazol e seus usos
BR112014016810A8 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112012014190B8 (pt) composição farmacêutica para o tratamento da síndrome do olho seco
BR112018067906A2 (pt) métodos de tratamento de depressão usando antagonistas do receptor de orexina-2
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
BR112013025047A2 (pt) composições nutricionais para aumentar os níveis de arginina e métodos para usar as mesmas
BR112017008993A2 (pt) métodos e composições especificamente para o tratamento de transtorno de déficit de atenção
BRPI0919020B8 (pt) uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
BR112015017251A8 (pt) composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
BR112015025684A2 (pt) método para proporcionar um ou mais opióide(s) a um indivíduo, forma de dosagem, método para tratar ou prevenir dor e método para tratar ou prevenir dependência ou vício
BR112018003842A2 (pt) método para inibir a absorção de lipídios e/ou promover a excreção de lipídios utilizando d-psicose
BR112018007128A2 (pt) compostos para a inibição de câncer e epigênese
MX340985B (es) Compuestos de n-heteroarilo.
Dall et al. NAD+ and NAFLD–caution, causality and careful optimism
BR112014009365A2 (pt) método para inibição da atividade de deubiquitinação
BR112018000242A2 (pt) composições nutricionais contendo fosfatidiletanolamina, esfingomielina e ácido doco-saexaenóico
BR112016028446A2 (pt) inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B15I Others concerning applications: loss of priority

Free format text: VIDE E-PARECER

B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]